Details

Autor(en) / Beteiligte

• Majumdar, Anup K.
• Yan, Kerri X.
• Selverian, Diana V.
• Barlas, Suna
• Constanzer, Marvin
• Dru, James
• McCrea, Jacqueline B.
• Ahmed, Tuli
• Frick, Glen S.
• Kraft, Walter K.
• Petty, Kevin J.
• Greenberg, Howard E.

Titel

Effect of Aprepitant on the Pharmacokinetics of Intravenous Midazolam

Ist Teil von

• Journal of clinical pharmacology, 2007-06, Vol.47 (6), p.744-750

Ort / Verlag

Oxford, UK: Blackwell Publishing Ltd

Erscheinungsjahr

2007

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Oral aprepitant 125 mg, an antiemetic and a moderate inhibitor of the metabolism of oral midazolam, was assessed for interaction with intravenous midazolam in 12 subjects randomized to intravenous midazolam 2 mg ± oral aprepitant 125 mg. The hypothesis was that midazolam AUC would not change by more than 2‐fold (consistent with no more than weak inhibition) when midazolam + aprepitant was compared with midazolam alone. An AUC geometric mean ratio (midazolam + aprepitant/midazolam) with 90% confidence interval upper bound ≤2.0 (an increase in midazolam felt to be of modest clinical significance in the highly monitored perioperative period) was prespecified. Aprepitant increased intravenous midazolam AUC0–∞ 1.47‐fold (90% confidence interval, 1.36–1.59), which fell within the prespecified criterion.